Defining new therapeutic paradigms for patients with ovarian cancer is of critical importance, given that this is a uniformly fatal disease for the vast majority of women afflicted by it. Of note, distinct gene therapeutic initiatives have been rapidly translated into clinical trials for ovarian cancer, several of which have been conducted by the investigators of this proposal. The implementation of these trials, however, has revealed limitations that relate primarily to the inadequacy of current vector systems to achieve efficient and specific tumor cell targeting and to the logistics and morbidity associated with invasive assessment of in vivo gene transfer. It is our hypothesis that the therapeutic utility of cancer gene therapy approaches for ovarian cancer will be substantially improved by the employment of a new generation of vector systems capable of efficient and tumor cell-specific transduction and by the application of novel noninvasive gene transfer imaging techniques. To address this hypothesis, we propose: 1) to determine the biodistribution and spectrum of toxicities associated with, and the imaging capabilities of an advanced generation adenoviral vector that is genetically modified to augment tumor tropism and to encode both a therapeutic gene and a receptor for gene transfer imaging when administered IP in animal models; 2) to determine the maximum tolerated dose, spectrum of toxicities, and antitumor activity of this novel gene therapeutic when administered IP in patients with recurrent ovarian cancer; 3) to assess the ability of this novel gene therapeutic to transfect target tumor cells in situ, to be imaged with nuclear scanning, and to elicit a host immune response when administered IP in patients with recurrent ovarian cancer; and 4) to enhance the antitumor activity of this novel therapeutic by incorporation of additional ovarian specific targeting peptides in the adenoviral vector and by using a bifunctional radiolabeled peptide. The aggregate of these studies will overcome the obstacles that are currently preventing gene therapy from reaching its potential as a new therapeutic paradigm for patients with ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA090547-04
Application #
7285712
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Song, Min-Kyung H
Project Start
2001-08-09
Project End
2012-01-31
Budget Start
2007-08-01
Budget End
2012-01-31
Support Year
4
Fiscal Year
2007
Total Cost
$205,761
Indirect Cost
Name
University of Alabama Birmingham
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Majumder, Kinjal; Rupp, Levi J; Yang-Iott, Katherine S et al. (2015) Domain-Specific and Stage-Intrinsic Changes in Tcrb Conformation during Thymocyte Development. J Immunol 195:1262-72
Koues, Olivia I; Kowalewski, Rodney A; Chang, Li-Wei et al. (2015) Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma. Immunity 42:186-98
Kim, Kenneth H; Dmitriev, Igor; O'Malley, Janis P et al. (2012) A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 18:3440-51
Saini, Vaibhav; Martyshkin, Dmitri V; Mirov, Sergei B et al. (2008) An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles. Small 4:262-9
Rocconi, Rodney P; Zhu, Zeng B; Stoff-Khalili, Mariam et al. (2007) Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 105:113-21
Breidenbach, Martina; Rein, Daniel T; Schondorf, Thomas et al. (2006) A new targeting approach for breast cancer gene therapy using the heparanase promoter. Cancer Lett 240:114-22
Mahasreshti, Parameshwar J; Kataram, Manjula; Wu, Hongju et al. (2006) Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol 100:521-32
Breidenbach, M; Rein, D T; Everts, M et al. (2005) Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 12:187-93
Wu, Hongju; Han, Tie; Belousova, Natalya et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79:3382-90
Wang, Minghui; Hemminki, Akseli; Siegal, Gene P et al. (2005) Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 96:341-8

Showing the most recent 10 out of 28 publications